Akynzeo (Fosnetupitant/Palonosetron) Patent Expiration, LOE Window & CMS Spending

Akynzeo (Fosnetupitant/Palonosetron) by Helsinn Healthcare Sa: FDA Orange Book core substance LOE 2032-05-23 (last listed 2037-06-02), 0 AB generics, $9.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHelsinn Healthcare Sa
FDA Application & PathwayN210493 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2032-05-23
Last Listed Patent or Exclusivity Date2037-06-02
Orange Book Patents (*PED Extensions)12 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$9.7M
2024 Medicare Part D Spend$4.8M
2024 Medicaid Spend$5.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel